PTGX · Protagonist Therapeutics, Inc

$155.10 +3.68 (+2.43%) At close · Aug 14

Market Cap

$10.04B

64.71M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$715,500	—	$5,839,204	$5,618,010	$686,880	$11,912	$12,871,506
Arturo Molina	M.D., M.S., F.A.C.P. Chief Medical Officer	$572,000	—	$1,601,610	$1,543,628	$366,080	$11,912	$4,095,230
Asif Ali	EVP, Chief Financial Officer	$500,000	—	$1,238,745	$1,192,502	$320,000	$6,242	$3,257,489

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$681,410	$112,432	$1,987,773	$6,119,129	$562,163	$10,912	$9,473,819
Arturo Molina	M.D., M.S., F.A.C.P. Chief Medical Officer	$550,000	$66,000	$614,775	$1,892,514	$330,000	$10,912	$3,464,201
Asif Ali	EVP, Chief Financial Officer	$465,000	$55,800	$491,820	$1,514,011	$279,000	$5,242	$2,810,873
Suneel Gupta	Ph.D. Chief Development Officer	$530,500	$63,660	$450,835	$1,387,844	$291,775	$10,912	$2,735,526

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$655,200	—	—	$6,041,100	$360,360	$10,912	$7,067,572
Suneel Gupta	Ph.D. Chief Development Officer	$515,205	—	$251,006	$1,245,977	$193,125	$10,876	$2,216,189
Asif Ali	EVP, Chief Financial Officer	$447,000	—	$129,306	$641,867	$178,800	$5,242	$1,402,215

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$630,000	—	$897,813	$4,211,963	$242,550	$10,912	$5,993,238
Suneel Gupta	Ph.D. Chief Development Officer	$500,000	—	$359,125	$1,684,785	$130,000	$10,894	$2,684,804

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$600,000	—	$589,250	$3,919,365	$429,000	$7,118	$5,544,733
Suneel Gupta	Chief Development Officer	$455,000	—	$282,840	$1,393,552	$236,600	$7,118	$2,375,110
David Y. Liu	Chief Research and Development Strategy Officer	$455,000	—	$235,700	$1,132,261	$233,188	$14,678	$2,070,827

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$565,000	—	—	$1,183,155	$473,894	$3,573	$2,225,622
Suneel Gupta	Chief Development Officer	$420,000	—	—	$427,950	$256,200	$4,120	$1,108,270
David Y. Liu	Chief Research and Development Strategy Officer	$441,300	—	—	$352,429	$266,987	$11,133	$1,071,849

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$545,000	—	$230,575	$814,355	$354,250	$4,164	$1,948,344
Suneel Gupta	Chief Development Officer	$377,467	—	$60,150	$693,789	$196,767	$3,564	$1,331,737
David Y. Liu	Chief Scientific Officer and Head of Discovery and Pre-Clinical Development	$428,450	—	$120,300	$424,881	$218,509	$7,458	$1,199,598

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dinesh Patel	President and Chief Executive Officer	$520,000	—	$1,127,739	$1,841,928	$221,000	$10,844	$3,721,511
David Y. Liu	Chief Scientific Officer and Head of Research and Development	$410,000	—	$382,389	$677,008	$141,500	$7,458	$1,618,355
Suneel Gupta	Chief Development Officer	—	—	—	—	—	$98,105	$98,105

Executive changes

Person	Role	Change	Effective	Filed
Lewis T. "Rusty" Williams, M.D., Ph.D.	Class I director	Appointed	2026-06-17	2026-06-18
Dinesh V. Patel, Ph.D.	Class I director	Appointed	2026-06-17	2026-06-18
Daniel N. Swisher Jr.	member of the Board of Directors	Resigned	2024-09-17	2024-09-20
Daniel N. Swisher, Jr.	Class I director	Appointed	2023-10-26	2023-10-30
Asif Ali	Executive Vice President, Chief Financial Officer	Appointed	2022-04-18	2022-03-31
Don Kalkofen	Chief Financial Officer	Resigned	2022-04-01	2022-03-23

Key facts CIK 1377121 CUSIP 74366E102 13F (30d) 326 filings 319 filers Visit website Investor relations